Study summary · research use only
Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This prospective longitudinal study of 121 adult human patients with erythropoietic protoporphyria (EPP) at a single Dutch center examined clinical and psychosocial features before and during afamelanotide treatment, using questionnaires including DS-14, SF-36, and EPP-QoL. At baseline, 5% of patients were unemployed, versus none during treatment, and full/part-time employment rose from 59.5% to 69.9% (p>0.05). EPP-QoL scores rose from 44% to 75% (p<0.001). Type-D personality was present in 27.4% of patients, whose social inhibition scores improved during treatment (p=0.019). SF-36 social functioning scores, lower than the Dutch population at baseline (74.4±27.3 vs 84.0±22.4), rose to 84.3±20.9 during treatment (p=0.001). The abstract reports afamelanotide treatment was associated with improved quality of life and social functioning, noting more research is needed.
Abstract
Erythropoietic protoporphyria (EPP) patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. However, there is limited information on the psychosocial aspects of EPP. To investigate the clinical features and social aspects of living with EPP, before and during afamelanotide treatment in the Netherlands. A single-center prospective longitudinal study of adult patients with EPP attending the Erasmus MC Rotterdam. Patients completed questionnaires, comprising demographic, clinical and social details, including two generic (DS-14 and SF-36) and a disease specific (EPP-QoL) QoL questionnaires. 121 adult EPP patients were included. The educational level of EPP patients seemed higher compared to the Dutch population (36% vs. 30% high-education, 42% vs. 37% middle-education). At baseline 5% of the EPP patients were unemployed, none were unemployed during afamelanotide treatment. Full- and part-time employment rate increased from 59.5% to 69.9% on afamelanotide treatment (p > 0.05). EPP-QoL improved from 44% to 75% on afamelanotide treatment (p < 0.001). Type-D personality was present in 27.4% of patients; their social inhibition scores improved significantly on afamelanotide treatment (p = 0.019). EPP patients scored low on the social functioning domain (SF-36) compared to the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4; respectively), and improved during afamelanotide treatment (84.3 ± 20.9, p = 0.001). EPP has a significant negative impact on social aspects, with less employment despite a higher education level. Afamelanotide treatment improves quality of life, social functioning and possibly employment rate. It is important to recognize the impact of EPP on social life, although, more research is needed.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.